In addition, PARP inhibitors reduced MDSC and immunosuppression-related Tregs in tumor tissue, spleen, and blood, which reversed the immunosuppressive TME and contributed to resensitizing tumor cells to immunotherapy (Ding et al., 2018). Here, PARP1 is linked to neoplasm.